Compare TONX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | KRRO |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0M | 150.0M |
| IPO Year | N/A | 2019 |
| Metric | TONX | KRRO |
|---|---|---|
| Price | $3.98 | $13.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | ★ 543.3K | 114.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $1.75 | $5.20 |
| 52 Week High | $8.23 | $55.89 |
| Indicator | TONX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 58.48 |
| Support Level | $2.96 | $9.51 |
| Resistance Level | $4.31 | $14.52 |
| Average True Range (ATR) | 0.48 | 0.95 |
| MACD | 0.03 | 0.32 |
| Stochastic Oscillator | 85.50 | 85.42 |
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.